SCHEMBL1075880

SCHEMBL1075880

Cc1ccc(C(=O)Nc2cc(C(F)(F)F)ccc2OC2CCN(C)CC2)cc1-c1cc2cnc(N)nc2c(-c2ccccn2)c1O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 9/20 0.58
LCK P06239 8/20 0.58
MAPK14 Q16539 7/20 0.58
JAK3 P52333 4/20 0.58
SRC P12931 2/20 0.58
TYK2 P29597 1/20 0.58
SYK P43405 1/20 0.58
BTK Q06187 1/20 0.58
CSF1R P07333 2/20 0.41
BRAF P15056 3/20 0.41
KIT P10721 3/20 0.40
ABL1 P00519 3/20 0.40
PDGFRB P09619 2/20 0.40
DDR1 Q08345 1/20 0.40
TEK Q02763 5/20 0.40
WNT3A P56704 1/20 0.39
FES P07332 1/20 0.39
RET P07949 1/20 0.39
FGFR1 P11362 1/20 0.39
PDGFRA P16234 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1078432 0.89 LCK (0.59) KDRLCKMAPK14JAK3SRC
SCHEMBL1078263 0.88 MAPK14 (0.60) KDRLCKMAPK14JAK3SRC
SCHEMBL1077490 0.84 LCK (0.60) KDRLCKMAPK14JAK3SRC
SCHEMBL1078199 0.83 LCK (0.58) KDRLCKMAPK14JAK3SRC
SCHEMBL1149116 0.81 LCK (0.48) KDRLCKMAPK14JAK3SRC
SCHEMBL1078657 0.80 LCK (0.61) KDRLCKMAPK14JAK3SYK
SCHEMBL1078530 0.79 DDR2 (0.56) BRAFKITABL1DDR1RET
SCHEMBL1078765 0.78 LCK (0.62) KDRLCKMAPK14JAK3SRC
SCHEMBL1077175 0.77 BRAF (0.52) BRAFKITDDR1
SCHEMBL1077587 0.76 KIT (0.61) CSF1RBRAFKITABL1RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2269993-B1 2-AMINOQUINAZOLINE DERIVATIVE KYOWA HAKKO KIRIN CO LTD (JP) 2013-02-27 EP disclosed
US-20110039845-A1 2-AMINOQUINAZOLINE DERIVATIVE KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-02-17 US disclosed
EP-2269993-A1 2-AMINOQUINAZOLINE DERIVATIVE Kyowa Hakko Kirin Co., Ltd. (JP) 2011-01-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110039845-A1 2-AMINOQUINAZOLINE DERIVATIVE H1-2, H1-3, H1-0 KDR 896/4885LCK 3187/4885MAPK14 2338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.